Background: Activation of cell surface CD30 by immobilized anti-CD30 monoclonal antibodies (mAbs) induces extremely rapid and intense apoptosis in human eosinophils in vitro. This anti-CD30 mAb-induced eosinophil apoptosis was inhibited by the addition of inhibitors of p38 and ERK1/2 mitogen-activated protein kinases (MAPKs). However, the signal transduction pathways other than for MAPKs remain unclear. In the present study, we tried to clarify the molecules involved in the induction of apoptosis after cross-linking of CD30. Methods: Purified human eosinophils were suspended in Iscove’s minimal essential medium supplemented with 10% FCS and 1 ng/ml IL-5 and then cultured for 4 h in plates precoated with anti-CD30 mAb (clone Ber-H8) in the presence or absence of various signal transduction inhibitors. Eosinophil apoptosis was assessed using annexin V and flow cytometry. Results: The addition of inhibitors of caspase-3, caspase-8, pan-caspases, nuclear factor ĸB and protein kinase C at reasonable concentrations did not alter anti-CD30 mAb-induced eosinophil apoptosis in vitro. However, apoptosis was inhibited by phosphatidylinositol 3-kinase (PI3K) inhibitors: wortmannin at very high concentrations (>1 µM) significantly and LY294002 at a reasonable concentration partially inhibited that apoptosis. Conclusions: Anti-CD30 mAb-induced eosinophil apoptosis is likely to be mediated mainly through MAPKs and partially through PI3K, but independent of caspase activation. Downstream signaling molecules of MAPK activation in eosinophils have to be clarified in future studies.

Keywords:
Apoptosis, CD30, Eosinophils, Signal transduction pathways
1.
Kay AB, Phipps S, Robinson DS: A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004;25:477–482.
2.
Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ: Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 2005;116:796–804.
3.
Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006;24:147–174.
4.
Ying S, Meng Q, Taborda-Barata L, Kay AB: Association of apoptosis of neutrophils and eosinophils and their ingestion by macrophages with resolution of the allergen-induced cutaneous late-phase response in atopic human subjects. Proc Assoc Am Physicians 1997;109:42–50.
5.
Haslett C: Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999;160:S5–S11.
6.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–2148.
7.
Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, Jarjour NN, Busse WW, Kelly EA: Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002;169:6452–6458.
8.
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029–1036.
9.
Broide DH: Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008;121:560–570.
10.
Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004;172:2186–2193.
11.
Matsumoto K, Terakawa M, Fukuda S, Saito H: Rapid and strong induction of apoptosis in human eosinophils by anti-CD30 mAb-coated microspheres and phagocytosis by macrophages. Int Arch Allergy Immunol 2007;143(suppl 1):60–67.
12.
Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992;68:421–427.
13.
Horie R, Watanabe T: CD30: expression and function in health and disease. Semin Immunol 1998;10:457–470.
14.
Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, Wakeham A, Mittruecker HW, Griesser H, Takimoto H, Schmits R, Shahinian A, Ohashi P, Penninger JM, Mak TW: Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice. Cell 1996;84:551–562.
15.
Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23–68.
16.
Hansel TT, De VI, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walker C: An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105–110.
17.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995;184:39–51.
18.
Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS: Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995;86:1437–1443.
19.
Walsh GM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ: Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood 1996;87:2815–2821.
20.
Blaylock MG, Sexton DW, Walsh GM: Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils. J Allergy Clin Immunol 1999;104:1244–1250.
21.
Nutku E, Aizawa H, Hudson SA, Bochner BS: Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014–5020.
22.
Clarke LE, Bayerl MG, Bruggeman RD, Mauger D, Ioffreda MD, Abou-Elella A, Helm KF: Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol 2005;29:452–459.
23.
Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R, Stein H, Durkop H: CD30-induced signaling is absent in Hodgkin’s cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008;172:510–520.
24.
Nery FC, Passos DO, Garcia VS, Kobarg J: Ki-1/57 interacts with RACK1 and is a substrate for the phosphorylation by phorbol 12-myristate 13-acetate-activated protein kinase C. J Biol Chem 2004;279:11444–11455.
25.
Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A: Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006;132:503–511.
26.
Wendtner CM, Schmitt B, Gruss HJ, Druker BJ, Emmerich B, Goodwin RG, Hallek M: CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin’s lymphoma cell line. Cancer Res 1995;55:4157–4161.
27.
Schneider C, Stohr D, Merz H, Hubinger G: Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30. Leuk Lymphoma 2004;45:1009–1015.
28.
Krysov SV, Rowley TF, Al-Shamkhani A: Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells. Mol Cancer Ther 2007;6:703–711.
29.
Atkinson EA, Barry M, Darmon AJ, Shostak I, Turner PC, Moyer RW, Bleackley RC: Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B. J Biol Chem 1998;273:21261–21266.
30.
Kobayashi T, Okamoto K, Kobata T, Hasunuma T, Sumida T, Nishioka K: Tumor necrosis factor alpha regulation of the FAS-mediated apoptosis-signaling pathway in synovial cells. Arthritis Rheum 1999;42:519–526.
31.
Adams J, Stein R: Novel inhibitors of the proteasome and their therapeutic use in inflammation. Annu Rep Med Chem 1996;31:279–288.
32.
Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270:14255–14258.
33.
Cousin JM, Haslett C, Rossi AG: Regulation of granulocyte apoptosis by PKC inhibition and elevation of [Ca2+]i. Biochem Soc Trans 1997;25:243S.
34.
Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH: Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009;30;284:30372–30382.
35.
Pinho V, Souza DG, Barsante MM, Hamer FP, De Freitas MS, Rossi AG, Teixeira MM: Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation. J Leukoc Biol 2005;77:800–810.
36.
Ferby I, Waga I, Kume K, Sakanaka C, Shimizu T: PAF-induced MAPK activation is inhibited by wortmannin in neutrophils and macrophages. Adv Exp Med Biol 1996;416:321–326.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.